AVERT System receives FDA clearance for controlled infusion of radiopaque contrast media in angiographic procedures

Download PDF Copy

Aug 23 2013

Osprey Medical Inc. (ASX: OSP) today announced that it has received U.S. FDA 510(k) clearance for its AVERT™ System.

The AVERT System is a proprietary technology designed to reduce the amount of dye injected and exposed to patients undergoing angiogram or diagnostic heart procedures. In a pilot human clinical study, the AVERT System was shown to reduce the amount of dye by up to 40% without compromising image quality. There are approximately 4.4 million angiogram and STEMI heart procedures performed annually in Western Europe and the United States. Utilizing the AVERT System on those patients significantly reduces the amount of dye used in these procedures

Mike McCormick President of Osprey Medical commented, “We are delighted to have achieved this important milestone. AVERT was not yet part of our plans when we undertook our IPO in May 2012. Developing the Avert System and obtaining FDA clearance in such a short period of time is testament to the capabilities of our team at Osprey and potentially opens up further exciting opportunities for the company. We will shortly begin to commercialize AVERT in a controlled manner to demonstrate awareness and adoption patterns among select key opinion leading physicians.”

Osprey is currently building product inventory, developing product labels to meet FDA requirements, and finalizing its U.S. sales plans. Upon completion of these activities, the Company will begin a controlled U.S. commercialization anticipated to commence in Texas in Q4 CY 2013.

About AVERT™ System

The Avert System consists of a re-usable contrast modulator with easy to adjust settings for the different types of contrast dyes. The disposable modulation reservoir easily loads into the contrast modulator unit and attaches to commonly used manual injection systems used by interventional cardiologists during heart procedures. Osprey received its FDA clearance for a marketing claim of “controlled infusion of dye”. The Company is currently conducting a pivotal trial with the aim of expanding its marketing claim to include the “reduction of CIN”.

AVERT System Benefits